Report Adverse Event or Product Quality Complaint   

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • CHEST 2026

American College of Chest Physicians (ACCP) CHEST Annual Meeting - 2026

October 18 - 21, 2026

  1. All
  2. Respiratory Unbranded
  3. AIRSUPRA (albuterol/budesonide)
  4. TEZSPIRE (tezepelumab)
  5. BREZTRI/TRIXEO

HTML

Harnessing guideline-based AI to identify patients at risk of asthma exacerbation or asthma-related death, and not on guideline-directed medical therapy

HTML

Patients and physicians' valuation of treatment goals in Chronic Obstructive Pulmonary Disease (COPD): changes over a period of around 10 years (ACORD & CONCORDANCE projects)

HTML

Patients with mild asthma and higher mannitol sensitivity show enhanced lung function recovery post-challenge if treated with repetitive albuterol-budesonide vs albuterol

HTML

Health status improvements by baseline biomarker levels and smoking status in patients with moderate to very severe chronic obstructive pulmonary disease receiving tezepelumab

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma with highly elevated blood eosinophil counts: a pooled analysis of NAVIGATOR and DIRECTION

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma by blood neutrophil and eosinophil counts: a pooled analysis of PATHWAY and NAVIGATOR

HTML

Healthcare resource utilization of patients with eosinophilic granulomatosis with polyangiitis: Real-world evidence from a US claims study

HTML

Budesonide/glycopyrrolate/formoterol fumarate effects on asthma control using the 7-item Asthma Control Questionnaire: insights from the KALOS and LOGOS studies

HTML

Sustained lung function benefit of 12-hours with budesonide/glycopyrrolate/formoterol fumarate therapy for inadequately controlled asthma: KALOS and LOGOS substudy results

HTML

Effect of tezepelumab on lung function in patients with OCS-dependent severe asthma by baseline inflammatory biomarker levels: results from the phase 3 SUNRISE study

HTML

In silico lung deposition of two single-inhaler triple therapies in patients with asthma

HTML

Harnessing guideline-based AI to identify patients at risk of asthma exacerbation or asthma-related death, and not on guideline-directed medical therapy

HTML

Patients and physicians' valuation of treatment goals in Chronic Obstructive Pulmonary Disease (COPD): changes over a period of around 10 years (ACORD & CONCORDANCE projects)

HTML

Healthcare resource utilization of patients with eosinophilic granulomatosis with polyangiitis: Real-world evidence from a US claims study

HTML

Patients with mild asthma and higher mannitol sensitivity show enhanced lung function recovery post-challenge if treated with repetitive albuterol-budesonide vs albuterol

HTML

Health status improvements by baseline biomarker levels and smoking status in patients with moderate to very severe chronic obstructive pulmonary disease receiving tezepelumab

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma with highly elevated blood eosinophil counts: a pooled analysis of NAVIGATOR and DIRECTION

HTML

Efficacy of tezepelumab in patients with severe, uncontrolled asthma by blood neutrophil and eosinophil counts: a pooled analysis of PATHWAY and NAVIGATOR

HTML

Effect of tezepelumab on lung function in patients with OCS-dependent severe asthma by baseline inflammatory biomarker levels: results from the phase 3 SUNRISE study

HTML

Budesonide/glycopyrrolate/formoterol fumarate effects on asthma control using the 7-item Asthma Control Questionnaire: insights from the KALOS and LOGOS studies

HTML

Sustained lung function benefit of 12-hours with budesonide/glycopyrrolate/formoterol fumarate therapy for inadequately controlled asthma: KALOS and LOGOS substudy results

HTML

In silico lung deposition of two single-inhaler triple therapies in patients with asthma

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-115625
Last Updated 9/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States